Hong Kong Daily Briefing

Livemint reported that WuXi AppTec — the Chinese biotech contract research organisation — was removed from the US Department of Defense's list of Chinese military companies. The removal is a significant positive for WuXi AppTec's US business relationships, particularly its CRO partnerships with Western pharmaceutical companies that had been reviewing contracts under the restriction. For HSI biotech names broadly, the de-restriction signals a potential thaw in bio-tech China-US tension and may accelerate WuXi's recovery in Western pharma partnerships.

FinanceAsia reported Franklin Templeton CEO Jenny Johnson's perspective on tokenisation and collateral use as driving the next wave of institutional crypto adoption. The significance for HK: the SAR's regulatory framework for digital assets positions it as the natural Asian hub for tokenised collateral markets. HKEX's digital asset licensing and the SFC's tokenised fund framework provide the infrastructure; institutional adoption by names like Franklin Templeton validates the thesis.

FinanceAsia flagged Hong Kong retail investors shifting toward ETFs for long-term wealth building in an environment of market volatility. The simultaneous renminbi rally (covered in the China brief) creates an incentive for Southbound flow as mainland investors find HK assets relatively cheaper on a CNY basis. The combined dynamic — retail ETF accumulation plus potential Southbound flow — could provide a technical bid under HSI at current levels.